title: Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.
abstract: BACKGROUND
  In most patients with recurrent glioma chemotherapy is the only remaining treatment option. In general results of chemotherapy in these patients are poor, and trials on new regimens are indicated. Because relatively good results have been achieved with combinations of platin compounds and etoposide, we investigated a dose-intensified cisplatin regimen with oral etoposide.
  
  
  METHODS
  Eligible patients, with recurrent glioma after surgery and radiation therapy were treated with two four week-cycles with cisplatin 70 mg/m2 on days 1, 8 and 15, combined with oral etoposide 50 mg daily on days 1-15. In responding or stabilized patients, treatment was continued with six four week-cycles of oral etoposide 50 mg/m2 on days 1-21. Toxicity was assessed using the NCI Common Toxicity Criteria, a 50% decrease in contrast enhancing area on MRI scan was considered a partial response. Time to progression was measured from the start of chemotherapy.
  
  
  RESULTS
  Sixteen patients were included, 11 were progressive during or immediately after the induction cycles. Two patients achieved a partial response with a time to progression of 42 and 58 weeks. Three patients were stable for 11, 14 and 15 weeks respectively. Toxicity was modest.
  
  
  CONCLUSIONS
  This dose-intensified cisplatin regimen did not result in a significant number of objective responses and even the number of 'stable disease' was small. Given the low response rate of this intensive treatment, we consider this intensive regimen inappropriate for these patients.
authors.affiliation: Department of Neuro-Oncology, Daniel den Hoed Cancer Clinic and University Hospital Rotterdam, The Netherlands. bent@neuh.azr.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: L
authors.initials: L
authors.lastname: Pronk
authors.forename: P A
authors.initials: PA
authors.lastname: Sillevis Smitt
authors.forename: C J
authors.initials: CJ
authors.lastname: Vecht
authors.forename: F A
authors.initials: FA
authors.lastname: Eskens
authors.forename: J
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D005047:Etoposide; D002945:Cisplatin